In 4000 Thai adults after a two-dose COVID-19 primary series, a single HXP-GPOVac booster met non-inferiority to VAXZEVRIA for day-14 neutralising antibodies (GMC ratio 0.83; seroconversion difference −2.35%); solicited AEs 43.7% vs 53.5%.
RCTn = 4,000
Prasert et al. Safety and immunogenicity of Thailand Government Pharmaceutical Organization (GPO) produced, COVID-19 vaccine, 10 μg HXP-GPOVac: A Phase III, double-blind, randomized trial in comparison with VAXZEVRIA